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Public debate and new nevirapine
toxicity data
Nevirapine was the first non-nucleoside drug (NNRTI) to be
approved by the Federal Drug Administration (FDA) for use in
combination therapy of HIV-1 infection in 1996. It has been
approved for use in children of 2 months or older, and
following the publication of the HIVNET 012 study in Uganda1
has been widely used as single-dose prophylaxis for prevention
of mother-to-child HIV transmission (MTCT) in resource-poor
settings.
Early in nevirapine development, a cutaneous
hypersensitivity rash occurring in the first 4 weeks of therapy
was recognised as a common side-effect, and registration
studies reported clinical hepatitis in approximately 1% of
individuals.2 Despite these recognised toxicities, cheap generic
formulations, including fixed-dose combinations, have been
manufactured in India and Brazil, making nevirapine one of
the most commonly prescribed antiretrovirals worldwide.
Clinical experience with the drug has been extensive;
however, it has recently attracted increased media scrutiny,
becoming embroiled in controversy.  Firstly an ongoing dispute
between Dr Jonathan Fishbein3 and his employers at the
National Institutes of Health (NIH) over the conduct of
HIVNET 012 was given wide media coverage when Associated
Press released articles accusing the NIH of conspiring to
suppress data about the safety of short-course nevirapine given
to African patients.4  Parallels were drawn with the infamous
Tuskegee study. The initial Associated Press report appeared on
13 December 2004, provoking a series of polarised responses
over the next few days from the Elizabeth Glaser Paediatric
AIDS Foundation,5 Project Inform,6 The National Institutes of
Health7 and the South African National Congress,8 and a
rebuttal from the researchers at Makerere and Johns Hopkins
universities.9 Concerns were expressed in leading scientific
journals (including Science,10 Nature11 and the BMJ12) that these
allegations might undermine MTCT programmes. Nevirapine-
related toxicities in pregnancy were highlighted by a study
published in 2004, reporting a death from fulminant hepatitis
in a Paediatric AIDS Clinical Trials Group study (PACTG
1022).13 Reports that intrapartum exposure to nevirapine was
associated with increased virological failure during subsequent
nevirapine treatment increased concerns.14
Finally, the US Federal Drug Administration issued a Public
Advisory for Nevirapine (Viramune), informing health care
providers of a safety-related change to the nevirapine package
insert.15 This advisory was based on data showing a higher risk
of serious liver toxicity in patients with preserved CD4 cell
counts commencing nevirapine. 
This article will review these new data and discuss resulting
changes in patient management in South Africa, both within
the national roll-out programme and other health sectors. 
Nevirapine toxicity and the FDA Public
Health Advisory
The FDA Public Health Advisory for Nevirapine issued on 19
January 2005 notified a change in nevirapine prescribing
information with a warning against starting nevirapine in
women with a CD4 cell count > 250 µl and in men with a count
> 400 µl.  The risk of developing a hepatic hypersensitivity
reaction in the first 6 weeks of nevirapine therapy had been
shown be increased 12-fold in women with CD4 counts > 250
and 5-fold in men with counts > 400 compared with women
with counts of < 250 and men with counts of < 400,
respectively.15
The recent reporting of such serious toxicity after 9 years of
nevirapine registration and widespread use highlights the
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Fig. 1. Percentage of patients with hepatotoxicity (AST/ALT > 5 × ULN),
clinical presentations and associated risk factors identified in a meta-
analysis of 17 studies including 2 545 nevirapine-treated subjects.
Hepatotoxicity occurred in 10%, and was associated with rash and/or
systemic symptoms in 3.9% of subjects and with rash in 2.2%.
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difficulties of quantifying rare adverse events.  The problem
was made more complicated because hepatic abnormalities are
common in HIV infection due to coinfections with hepatitis B
and C, alcoholism, substance abuse and co-administration of
other medications including antiretrovirals associated with
hepatotoxicity. Also data accumulated from different sources
appeared to give conflicting results. Large cohort studies such
as the EuroSIDA study of 4 639 patients initiating therapy with
an NNRTI reported reassuringly low rates of ALT/AST
elevations (> 5 × upper level of normal (ULN)) of 1.7% for
efavirenz and 2.1% for nevirapine, and liver failure rates of 0.4
and 0.3 cases per 100 person-years, respectively.16 However,
toxicity databases raised concern by reporting serious
hepatotoxicities and deaths, while controlled trials gave widely
differing estimates of nevirapine hepatic risk.13,17
A fuller picture has only developed with the recognition that
there is a spectrum of drug-related hepatic toxicity in treated
HIV infection. Low elevations of AST/ALT (< 5 × ULN) occur
frequently in patients on antiretroviral therapy during the
course of treatment, are nonspecific and have multiple
causations. Moderate elevations (> 5 × ULN) occur in 6% of
treated patients, and are associated with co-infection with
hepatitis C (relative risk (RR) = 5.2), elevation of baseline
AST/ALT (RR = 4.3) and hepatitis B co-infection (RR = 2.3) and
weakly associated with nevirapine.18 Hypersensitivity hepatitis
(defined as AST/ALT > 5 × ULN with systemic symptoms
and/or rash occurring in the first 42 days of antiretroviral
therapy) is a specific entity strongly associated with 
nevirapine use (RR = 11.2) and is modified by gender and 
CD4 count (Fig. 1).19
The low reported incidence rate of nevirapine hyper-
sensitivity hepatitis (cases/100 person-years) in cohort studies
may in part be due to a few events occurring early in treatment
divided by a very large time denominator of total cohort
follow-up. A genetic predisposition to hypersensitivity
reactions has recently been recognised to be associated with a
human leucocyte antigen marker (HLA-DRB1*0101).20 Some of
the variability in reported toxicity between populations may
also be related to a differential HLA-DRB1 carriage frequency,
which is high in USA and European Caucasian populations,
but lower in African and Asian populations.21
Single-dose nevirapine for prevention
of MTCT of HIV and HIVNET 012
The Associated Press articles of  13 - 15 December raised
concerns that there may be many unreported adverse events
related to nevirapine use. The investigators at Makerere
University and Johns Hopkins denied suppressing drug-related
toxicities in the safety reporting9 and stated that no deaths or
serious adverse events definitely related to nevirapine occurred
during the study.   
While the debate around HIVNET 012 has implications for
design and conduct of studies in resource-poor settings, it does
not give any direct evidence of toxicity of single-dose
nevirapine in pregnant women. Several large studies and data
sets have subsequently established the safety of single-dose
nevirapine alone and in combination with other antiretrovirals
in a wide variety of settings. No significant clinical or
laboratory toxicities were observed in 1 600 women receiving
single-dose nevirapine in comparative clinical trials.22 A South
African study involving 1 317 pregnant women, of whom 655
received single-dose nevirapine and 662 received zidovudine
with lamivudine, reported in 2003 no significant laboratory or
clinical toxicities in the mothers. The rate of hepatic events in
the infants was 3.3% in the ZDV/3TC and 2.7% in the NVP
arms.23 In a study of 1 270 non-breast-feeding women recruited
in the US, Europe, Brazil and the Bahamas to receive single-
dose nevirapine or placebo in combination with standard ART,
the HIV transmission rate was 1.5% and there were no
significant safety concerns. Elevated transaminases, defined as
> 2.5 × ULN, occurred in 1% of subjects.24
Between January 2001 and February 2003, 1 445 Thai women
receiving zidovudine in the third trimester of pregnancy were
given additional single-dose nevirapine, with no reported
grade 3 or 4 hepatotoxicity. Of the 216 serious adverse events
that occurred during the study, 59% were pregnancy-related
and 26% HIV-related; 7% of women developed anaemia
possibly related to zidovudine, and there was a single case of
allergic reaction which may have been related to nevirapine.25
Up to 2004, no serious nevirapine-related liver toxicity had
been reported to the USA FDA Medwatch programme for
women receiving single-dose nevirapine.26 This combined
weight of evidence indicates that single-dose nevirapine alone
and in combination with other ARTs is free of significant
hepatic toxicity and can be prescribed safely in pregnancy.
Single-dose nevirapine is less effective than more complex
regimens, however, and there is increasing evidence that
virological suppression to < 50 copies/ml is lower in women
who have received single-dose nevirapine subsequently treated
with NNRTIs.14 The cheapness and ease of administration
however continue to makes it an attractive MTCT prevention
strategy in settings where more complex regimens are not
available.  
Use of continuous nevirapine in
pregnancy and PACTG 1022
The use of antiretrovirals in pregnancy impacts on both
maternal and fetal health. Nevirapine is an FDA category C
drug, indicating no teratogenicity in animal studies but a lack
of well-controlled trials in pregnant women. The antiretroviral
pregnancy registry, however, has not shown to date that
nevirapine use is associated with increased birth defects.27
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Nevirapine-containing regimens have been widely used in
MTCT programmes28 and together with other interventions
have brought transmission rates to < 1%.28,29 Women in
industrialised societies frequently start ART for the first time
during pregnancy, the majority having CD4 cell counts of > 250
cells/µl.28
The risk of nevirapine to maternal health was highlighted in
June 2004 by the publication of the PACTG 1022 comparative
study of nelfinavir and nevirapine in pregnancy.13 The study
received prominence because a woman with a baseline CD4
count of 330/µl developed > 5 × ULN AST at 4 weeks,
continued receiving nevirapine for a further 6 days and
subsequently died of hepatic necrosis. The study was small and
although 17.6% of women in the nevirapine arm developed
AST/ALT > 5 × ULN, the confidence intervals for this estimate
are very wide (95% CI –0.5 to +36), encompassing rates
reported in all other studies. The continuation of nevirapine in
the presence of an elevated AST may also have contributed to
the maternal death. The authors raised the question of whether
pregnancy could be an independent risk factor for nevirapine
toxicity. Six deaths from hepatic failure occurring during
pregnancy and the puerperium have been reported to the FDA
Adverse Event Reporting System.26 Three deaths were from
hepatic necrosis associated with NVP and 3 from lactic acidosis
associated with ddI/d4T-containing regimens. However owing
to lack of a denominator it is difficult to use these data to
establish pregnancy as an independent risk factor for hepatitis.
Retrospective chart reviews of women receiving nevirapine
have not shown increased hepatotoxicity compared with non-
pregnant populations.30,31 Pregnancy may therefore not be a
specific risk factor; however, nevirapine hypersensitivity
reactions are more frequent in women with CD4 counts above
250 cells/µl and this is a profile that frequently matches
pregnant women receiving MTCT prophylaxis.
Nevirapine use in post-exposure
prophylaxis
Nevirapine has characteristics that make it potentially
attractive for post HIV-exposure prophylaxis (PEP), including
rapid antiviral activity of the parent molecule, which does not
require intracellular phosphorylation, and a low pill burden. In
September 2000, two cases of life-threatening hepatotoxicity,
including one requiring liver transplantation, were reported in
health workers receiving continuous nevirapine for PEP.32 Up
to September 2000 the FDA MedWatch adverse event
monitoring programme had received 22 reports of serious
adverse events, 12 of which were hepatic and 14 cutaneous, in
individuals receiving nevirapine-containing PEP regimens.33 In
March 2001 a letter in The Lancet reported a high frequency of
serious adverse events among a series of 57 individuals
receiving nevirapine PEP.34 The use of nevirapine for PEP was
recently re-explored in a report of 120 individuals treated with
200 mg nevirapine for 4 days together with 2 nucleoside
reverse transcriptase inhibitors for 28 days at the University
Hospital of Strasbourg.35 Nevirapine was well tolerated in this
regimen, but minor elevations in ALT were reported in 6
individuals (5.6%). Current PEP guidelines from the US,
Europe and the UK specifically discourage use of nevirapine
for PEP. 
Implications of new nevirapine data
for antiretroviral programmes in South
Africa
Risk analyses on which the FDA advisory was based, derived
data from clinical trial data. Although a genetic predisposition
has been postulated and race was associated with hepatitis risk
in some individual studies, it did not remain as a significant
association in the overall meta-analysis. Whereas the FDA
advisory on changing prescribing information has little impact
in developing countries where there is easy availability of
alternative ARVs, in resource-poor settings alternatives are
limited by both cost and availability. Therefore the risk-benefit
analysis may be very different from that in industrialised
settings.
Single-dose nevirapine for MTCT 
While single-dose nevirapine for MTCT is not optimal as far as
efficacy is concerned and may negatively impact on subsequent
maternal virological response to ART, it has been demonstrated
to be safe from serious hepatic toxicity.
Post-exposure prophylaxis (PEP)
Use of nevirapine for PEP has been associated with
unacceptable toxicity and as safer alternatives are available
there is no role for nevirapine in PEP regimens in South Africa. 
Initiating and switching combination therapies 
Present World Health Organization and South African
guidelines recommend initiation of ART with NNRTIs.
Efavirenz is the only alternative NNRTI available in South
Africa. It has a similar efficacy to nevirapine36 but a different
toxicity profile and is a possible teratogen, and should be
avoided in women of child-bearing potential (WOCBP).
Nevirapine therefore continues to fill an important role in
combination therapy until cheap and safe alternatives are
available. Most current ART guidelines do not recommend
initiating therapy for males with CD4 counts > 400 cells/µl and
those with lower CD4 cell counts can safely initiate ART with
either NVP or EFV, the choice being determined by toxicity
profile and/or cost. 
In contrast, WOCBP with high CD4 cell counts frequently
initiate combination therapy in industrialised societies during
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pregnancy and an increasing number of South African women
with CD4 cell counts that have risen above 250/µl  wish to
switch from EFV before falling pregnant. Women who initiate
or switched to nevirapine at a CD4 cell count >250 cells/µl are
now recognised to be at high risk of hypersensitivity reaction
and will require alternative management strategies as outlined
in Table I.    
Conclusion
Hepatic toxicity occurs in approximately 6% of patients taking
ART and is due to multiple causes with various risk factors.
Nine years after registration of nevirapine, early
hypersensitivity reactions, occurring in approximately 2% of
patients, have been recognised to be a distinct clinical entity
strongly associated with nevirapine use, female gender and a
high CD4 cell count. This new insight resulted from a more
precise syndrome definition and a meta-analysis of clinical
trials. Long-term use of nevirapine has a similar adverse event
rate as alternative therapies and therefore continues to have a
major role in HIV patient management. Laboratory monitoring
of liver function tests and increased clinical vigilance is
required to identify hypersensitivity reactions, consisting of
elevated hepatic enzymes with rash and/or other clinical
symptoms such as fever, nausea and abdominal pain, occurring
in the initial 6 weeks of nevirapine therapy.  Liver function
tests should be performed when a nevirapine rash is present.
Once a diagnosis of nevirapine hypersensitivity reaction is
made, or strongly suspected, nevirapine must be discontinued
as soon as possible and not rechallenged. 
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In a recent issue of the Journal,1 views were expressed that our
national private sector caesarean section (CS) rate is too high at
over 60%, and government and/or funders are likely to
intervene unless doctors begin to self-regulate by developing
appropriate protocols and guidelines.  This is not a new issue
for South Africa or for medically insured populations around
the world, and the sheer volume of literature on the subject of
high CS rates indicates that it is unlikely one will reach
consensus on a national target CS rate simply by means of a
decree, whether issued by providers or regulators.  
However, what is not clear from Chris Bateman’s article1 is
whether the core issue is one of women’s (and children’s)
health, of consumption of scarce financial resources, of concern
about doctors being exposed to medico-legal risk, or of a
patient’s right to choose a health intervention that may not be
medically necessary.
Is the concern around health or costs?
We contend that this is not primarily about maternal and child
health or about exposure to unnecessary anaesthetic and
operative risk, because if the country was truly concerned
about such matters we would have acted long ago to reduce
rates of cosmetic surgery.  In general we accept a patient’s right
to undergo procedures such as breast reduction, augmentation
and liposuction, but deal with them on the basis of the
patient’s willingness to self-fund, assuming of course that
consent for surgery has always been fully informed and all
risks have been explained.  Bateman’s article implies that in the
case of CS the risks are not fully explained and that women
might be unreasonably and unnecessarily influenced by their
doctor’s bias.1  Overseas research does not consistently support
this contention; in fact several recent studies2,3 show that the
overwhelming majority of obstetricians favour vaginal
delivery. However the data further indicate that most
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